GR

Green Cross Holdings

A biotech firm in biopharma, diagnostics, digital health, and consumer wellness products.

005250 | KO

Overview

Corporate Details

ISIN(s):
KR7005250006
LEI:
Country:
South Korea
Address:
경기 용인시 구성읍 동백리 (주)녹십자 303, 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Green Cross Holdings is a holding company focused on the healthcare and biotechnology industries. Its core operations are divided into four main segments: Biopharma & Innovative Technology, Diagnosis, Digital Healthcare, and Consumer Health. The Biopharma division is a key area, specializing in the development, manufacturing, and marketing of plasma derivatives, protein therapeutics, and vaccines. The company is recognized for developing the world's first pandemic hemorrhagic fever vaccine and South Korea's first flu vaccine. The Diagnosis segment provides in-vitro diagnostic services and supports clinical trials. Its Digital Healthcare platform facilitates remote medical services and monitoring, while the Consumer Health division offers functional foods and wellness products. The company maintains a global presence, exporting its products to numerous countries.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 212.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 4.6 MB
2025-06-26 00:00
Prospectus
투자설명서
Korean 4.8 MB
2025-06-26 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 54.8 KB
2025-06-25 00:00
Registration Form
[발행조건확정]증권신고서(채무증권)
Korean 15.4 KB
2025-06-20 00:00
Prospectus
[기재정정]증권신고서(채무증권)
Korean 5.5 MB
2025-06-20 00:00
Registration Form
[발행조건확정]증권신고서(채무증권)
Korean 612.7 KB
2025-06-19 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 18.1 KB
2025-06-16 00:00
Registration Form
증권신고서(채무증권)
Korean 4.7 MB
2025-06-02 00:00
Governance Information
기업지배구조보고서공시
Korean 852.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 3.9 MB
2025-04-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 29.3 KB
2025-04-25 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 92.4 KB
2025-04-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 258.1 KB
2025-04-11 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 83.3 KB

Automate Your Workflow. Get a real-time feed of all Green Cross Holdings filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Green Cross Holdings

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Green Cross Holdings via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX
InMed Pharmaceuticals Inc. Logo
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America
INM

Talk to a Data Expert

Have a question? We'll get back to you promptly.